micro-community-banner
 
  • Saved

2yr
Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis

Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis

Source : https://www.frontiersin.org/articles/10.3389/fmed.2022.1022889/abstract

Prurigo nodularis (PN) is a chronic, pruritic, inflammatory skin disease characterized by hyperkeratotic nodules on the trunk and extremities. While there is growing research on the immunological basis of PN,...


Conclusions: We present novel findings demonstrating increased neurotrophic and extracellular matrix remodeling signatures in PN compared to AD, possibly explaining the morphological differences in their lesions. These signatures may therefore be important components of the PN pathogenesis and may serve as therapeutic targets.


  • Saved

2yr
The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers

The Impact of Psoriasis and Atopic Dermatitis on Quality of Life: A Literature Research on Biomarkers

Source : https://www.mdpi.com/2075-1729/12/12/2026

Psoriasis (PSO) and Atopic dermatitis (AD) are common inflammatory skin diseases that affect people of all ages globally. They negatively impact the quality of life (QoL) of patients in health-related...


Conclusions: These biomarkers are potential life quality impairment prediction factors in PSO and AD, this could be very relevant. A challenge in future will be the development of a mechanism to get an adequate amount of sweat, as perspiration may vary from individual to individual. Additionally, the concentration of the biomarkers may vary in...

  • 2yr
    I wonder if data like this may ultimately prove more relevant for those conducting clinical studies or for insurance companies than it does day-to-day in our clinics.
  • 2yr
    An interesting concept, but not very relevant to everyday clinical practice and caring for our AD and PsO patients.
  • Saved

2yr
Group Recommends Clinical Instruments to Measure Atopic Eczema Burden - PubMed

Group Recommends Clinical Instruments to Measure Atopic Eczema Burden - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36472604/

The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....


Conclusions: According to the HOME group, the recommended instruments can help monitor patient burden, assist in shared decision-making, indicate quality of care, and support value-based health care.


  • Saved

2yr
Exome variants associated with asthma and allergy - PubMed

Exome variants associated with asthma and allergy - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36470944/

The mutational spectrum of asthma and allergy associated genes is not known although recent biobank based exome sequencing studies included these traits. We therefore conducted a secondary analysis of exome...


Conclusions: It seems from this analysis, that the genetics of atopic dermatitis is clearly separated from allergic rhinitis and asthma. Atopic dermatitis is already sufficiently described by filaggrin mutations which is in line with our earlier observation that atopic dermatitis is genetically a largely different disease. Filaggrin mutations...

  • Saved

2yr
Safety of topical JAKi for atopic dermatitis

Atopic dermatitis (AD), also known as atopic eczema, is a chronic, pruritic, relapsing inflammatory dermatological condition. Treatment mainly aims at reducing itch and inflammation, eliminating flare-ups, and reducing side effects. Topical agents are considered as a primary treatment for mild-to-moderate AD and include topical corticosteroids, topical calcineurin inhibitors (TCI), topical phosphodiesterase 4 (PDE4) inhibitor crisaborole (Eucrisa), and more recently, the first topical Janus kinase (JAK) inhibitor, ruxolitinib cream 1.5% (Opzelura) approved for use in patients with mild-to-moderate AD.



In the topical ruxolitinib clinical studies, more than half of patients with mild-to-moderate AD achieved clear or almost clear skin as well as significant itch relief after 8 weeks. Nasopharyngitis was the most common AE experienced by 3% of patients vs 1% in control patients. Other AEs included diarrhea, bronchitis, ear infections, increase in eosinophil count, and hives, which occurred in 1% of ruxolitinib patients and less than 1% for control patients.



There is a black box warning on the label, which is primarily based on the oral JAKi, tafacitinib (Xeljanz, Pfizer). It is important to note that about 6% of topical ruxolitinib cream is absorbed into the bloodstream, a roughly 85% reduction from oral ruxolitinib.



What are your thoughts on the safety of a topical vs oral JAKi? What has been your experience with AEs from the topical therapies?


  • 2yr
    Topical nonsteroidal product under consideration, has been quite effective as an adjunctive therapy to injectable Dupixent and oral RinVoq. I have had good experience with both products. I have about Show More
  • 3yr
    Very beneficial that the topical route has a low systemic absorption rate as opposed to the oral method. I find it a challenge to prescribe the newer medication due to Show More

Show More Comments